Role of TIM-3 in ovarian cancer

Xu, Y; Zhang, H; Huang, Y; Rui, X; Zheng, F

Xu, Y; Zhang, H; Huang, Y; Rui, X; Zheng, F.

Afiliação

Xu, Y; The Third Affiliated Hospital of Soochow University. Department of Gynecology. Changzhou. China
Zhang, H; University of South Florida. College of Public Health. Department of Epidemiology and Biostatistics. Tampa. USA
Huang, Y; The Third Affiliated Hospital of Soochow University. Department of Gynecology. Changzhou. China
Rui, X; The Third Affiliated Hospital of Soochow University. Department of Gynecology. Changzhou. China
Zheng, F; The Third Affiliated Hospital of Soochow University. Department of Gynecology. Changzhou. China

Clin. transl. oncol. (Print) ; 19(9): 1079-1083, sept. 2017. ilus

Artigo em Inglês | IBECS | ID: ibc-165208

Biblioteca responsável: ES1.1

Localização: BNCS

ABSTRACT
RESUMEN

ABSTRACT

Evidences have suggested that immunotherapy for ovarian cancer is effective. Immune checkpoints have emerged in the field of cancer immunotherapy. Multiple studies have shown negative regulation of TIM-3 expression on CD4+ and CD8+ T cells and other immunocytes. Overexpression of TIM-3 in innate immune cells has been found in certain types of tumor. The blockade of TIM-3 leads to sustained anti-tumor reactions. TIM-3 plays an inhibitive role for immunity in ovarian cancer. TIM-3 is involved in the development of various subtypes of ovarian cancer and thus has the potential to be a therapeutic target for treatment of ovarian cancer (AU)

RESUMEN

No disponible

Assuntos

Humanos; Feminino; Biomarcadores Tumorais/análise; Neoplasias Ovarianas/diagnóstico; Neoplasias Ovarianas/patologia; Imunoterapia/métodos; Imunidade Celular; Anticorpos Antineoplásicos/análise; Homeostase; Antígenos CD4/análise; Relação CD4-CD8/métodos; Terapia de Alvo Molecular/métodos; Hemostasia/imunologia

Buscar no Google

Adicionar na Minha BVS

Imprimir

XML

Coleções: Bases de dados nacionais / Espanha Base de dados: IBECS Assunto principal: Neoplasias Ovarianas / Biomarcadores Tumorais / Imunidade Celular / Imunoterapia / Anticorpos Antineoplásicos Limite: Feminino / Humanos Idioma: Inglês Revista: Clin. transl. oncol. (Print) Ano de publicação: 2017 Tipo de documento: Artigo Instituição/País de afiliação: The Third Affiliated Hospital of Soochow University/China / University of South Florida/USA

Buscar no Google

Adicionar na Minha BVS

Imprimir

XML